2019
DOI: 10.3892/ol.2019.11097
|View full text |Cite
|
Sign up to set email alerts
|

PRSS1 genotype is associated with prognosis in patients with pancreatic ductal adenocarcinoma

Abstract: The prognostic value of the genotype of the PRSS1 gene in patients with pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. The aim of the present study was to evaluate the association between the PRSS1 genotype and clinicopathological characteristics of patients with PDAC, as well as to explore the prognostic significance of the PRSS1 genotype in patients with PDAC. A total of 124 patients with PDAC patients were included in the current study and the PRSS1 genotype of the enrolled patients was … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 21 publications
0
2
0
Order By: Relevance
“…In PDAC-1 and PDAC-2 we see shared copy number loss of tumor supressor genes CDKN2A, SMAD4 and BRCA2 25 , 29 . In PDAC-2 we observed a subclonal amplification of PRSS1 , a mutation that was fixed within our sampling for PDAC-1 and is associated with tumor size, tumor node metastasis rate 30 . This suggests that while the lines have the same origin, each culture captured different subsets of tumor clonal populations.…”
Section: Resultsmentioning
confidence: 61%
“…In PDAC-1 and PDAC-2 we see shared copy number loss of tumor supressor genes CDKN2A, SMAD4 and BRCA2 25 , 29 . In PDAC-2 we observed a subclonal amplification of PRSS1 , a mutation that was fixed within our sampling for PDAC-1 and is associated with tumor size, tumor node metastasis rate 30 . This suggests that while the lines have the same origin, each culture captured different subsets of tumor clonal populations.…”
Section: Resultsmentioning
confidence: 61%
“…In PDAC-1 and PDAC-2 we see shared copy number loss of tumor suppressor genes CDKN2A, SMAD4 and BRCA2 25,27 . In PDAC-2 we observed a subclonal amplification of PRSS1, a mutation that was fixed within our sampling for PDAC-1 and is associated with tumor size and a higher tumor node metastasis (TNM) stage 28 . This suggests that while the lines have the same origin, each culture captured different subsets of tumor clonal populations.…”
mentioning
confidence: 73%